USPTO serial 79348988
MEPSGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 3, 2024
- Examiner
- CORNWELL, ANDREA B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MEPSGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
LEIGH ANN LINDQUIST
LEIGH ANN LINDQUIST SUGHRUE MION PLLC2000 PENNSYLVANIA AVENUE NWSUITE 9000WASHINGTON, DC 20006Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for treating respiratory diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of central nervous system (CNS) diseases; stimulants for the central nervous system; pharmaceutical preparations for tumor treatment; tissue- regenerative pharmaceutical preparations; pharmaceutical preparations for use in tissue transplantation; clinical diagnostic reagents; clinical medical reagents; pharmaceuticals for the treatment of Parkinson's disease, Alzheimer's disease, Neurocognitive disorder, Neurodegenerative disease, Cancer, Brain disease; pharmaceutical compositions for treating Parkinson's disease, Alzheimer's disease, Neurocognitive disorder, Neurodegenerative disease, cancer, and brain disease; pharmaceutical drugs for treating Parkinson's disease, Alzheimer's disease, Neurocognitive disorder, Neurodegenerative disease, cancer, and brain disease; cells for medical purposes; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the prevention of inflammatory disorders; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular pharmaceuticals; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular treatment preparations; cardiovascular pharmaceutical preparations; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for immunity adjustment; pharmaceutical agents affecting metabolism; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical products for the treatment of infectious diseases | ACTIVE | — |
| 009 | Biochips for research or scientific purposes; biochip analyzing apparatus, namely, electronic biochip inspection device for testing functionality of biochips; apparatus for inspecting biochips for laboratory use, namely, electronic biochip inspection device for testing functionality of biochips; apparatus for analyzing biochips for laboratory use, namely, electronic biochip analysis device for analyzing functionality of biochips; apparatus for manufacturing biochips for laboratory use, namely, electronic installations for the remote control of industrial biochip manufacturing operations; laboratory apparatus for analyzing biological pharmaceuticals, namely, laboratory analysis device for analyzing efficacy, potency, and toxicity evaluations of biological pharmaceuticals; microchips | ACTIVE | — |
| 010 | Medical diagnostic apparatus for the detection of cardiovascular diseases; medical apparatus and instruments for use in medical examination and treatment of cardiovascular diseases; cell culture instruments for medical use, namely, cell culture chambers | ACTIVE | — |
| 035 | Wholesale store services featuring cell growth media for growing cells for use in scientific research; retail store services featuring cell growth media for growing cells for use in scientific research; wholesale store services featuring biological preparation for use in cell cultures other than for medical or veterinary use; retail store services featuring biological preparation for use in cell cultures other than for medical or veterinary use; wholesale store services featuring pharmaceutical preparations for the treatment of cells; retail store services featuring pharmaceutical preparations for the treatment of cells; wholesale store services featuring cardiovascular pharmaceuticals; retail store services featuring cardiovascular pharmaceuticals; wholesale store services featuring chemico-pharmaceutical preparations; retail store services featuring chemico-pharmaceutical preparations; wholesale store services featuring medical instruments; retail store services featuring medical instruments; wholesale store services featuring medical apparatus and instruments; retail store services featuring medical apparatus and instruments; wholesale store services featuring biological preparations for medical or veterinary purposes; retail store services featuring biological preparations for medical or veterinary purposes; wholesale store services featuring biotechnological preparations for medical purposes; retail store services featuring biotechnological preparations for medical purposes; wholesale store services featuring biological reagents for medical purposes; retail store services featuring biological reagents for medical purposes; wholesale store services featuring biological tissue cultures for medical purposes; retail store services featuring biological tissue cultures for medical purposes; wholesale store services featuring biological preparations for medical purposes; retail store services featuring biological preparations for medical purposes; wholesale store services featuring living cells for medical purposes; retail store services featuring living cells for medical purposes; wholesale store services featuring cells for medical purposes; retail store services featuring cells for medical purposes; wholesale store services featuring cell culture instruments for medical use; retail store services featuring cell culture instruments for medical use; wholesale store services featuring cardiovascular agents for medical purposes; retail store services featuring cardiovascular agents for medical purposes; wholesale store services featuring drugs for medical purposes; retail store services featuring drugs for medical purposes; wholesale store services featuring stem cells for medical purposes; retail store services featuring stem cells for medical purposes; wholesale store services featuring chemical preparations for medical purposes; retail store services featuring chemical preparations for medical purposes | ACTIVE | — |
| 042 | Crude medicines research; drug discovery services; development of cell therapy products; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; pharmaceutical drug development; research on the subject of pharmaceuticals; scientific research in the field of pharmacy; medical studies in the nature of medical and scientific research, namely, conducting clinical trials for others, and translational research and medical and scientific research; scientific research services for medical purposes in the field of cancerous diseases, CNS diseases, and brain diseases; drug delivery, medicinal effect, Biological or biotechnological research for medical products; development of biotechnology, namely, medical drug and biochip products; biotechnology research; laboratory research in the field of biology; development of biologics, namely, vaccine and therapeutic drug products; research in the field of chemistry; technological studies in the nature of biotechnology and microfluidics research; research and development of medical equipment; development of medical devices; conducting clinical trials in the field of cardiovascular disease; conducting early efficacy, potency, and toxicity evaluations in the field of new pharmaceuticals; conducting early pharmaceutical product evaluations in the field of new pharmaceuticals; testing of pharmaceuticals; laboratory research services relating to pharmaceuticals; providing information on the testing, inspection, research of medical products; consultancy in the field of testing, inspection, and research of medical products, namely, pharmaceuticals, pharmaceutical preparations and pharmaceutical compositions; pharmaceutical product evaluation; design of devices for biological medicine analysis; development of devices for biological chemicals analysis; development of devices for biochemical chemicals; microchip design services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MEPSGEN Co., LTD.
- Other trademarks owned by MEPSGEN Co., LTD.
- Other trademarks owned by MEPSGEN Co., LTD.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named MEPSGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 29, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Mar 8, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 16, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 16, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 3, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 3, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 3, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 1, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 18, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 18, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 11, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 29, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 16, 2024 | EXPT | EXPARTE APPEAL TERMINATED | — |
| May 16, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 16, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 16, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 16, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 16, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 14, 2024 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| May 14, 2024 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| May 14, 2024 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Apr 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 29, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 3, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 14, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 14, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 14, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 14, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 14, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 1, 2023 | DMCC | DATA MODIFICATION COMPLETED | — |
| Nov 1, 2023 | ALIE | ASSIGNED TO LIE | — |
| Oct 18, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 17, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 17, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 10, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 17, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 17, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 25, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 24, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 16, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 13, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 9, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 8, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |